Multiple P2Y receptors couple to calcium-dependent, chloride channels in smooth muscle cells of the rat pulmonary artery
详细信息 查看全文
- 作者：Krongkarn Chootip (1) (2)
Alison M Gurney (1)
Charles Kennedy (1) - 刊名：Respiratory Research
- 出版年：2005
- 出版时间：December 2005
- 年：2005
- 卷：6
- 期：1
- 全文大小：934KB
- 参考文献：1. Burnstock G, Kennedy C: A dual function for adenosine triphosphate in the regulation of vascular tone: excitatory cotransmitter with noradrenaline from perivascular nerves and locally released inhibitory intravascular agent. / Circ Res 1986, 58:319-30.
2. Boarder MR, Hourani MO: The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. / Trends Pharmacol Sci 1998, 19:99-07. CrossRef
3. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. / Pharmacol Rev 1998, 50:413-91.
4. Bakhramov A, Hartley SA, Salter KJ, Kozlowski RZ: Contractile agonists preferentially activate Cl - over K + currents in arterial myocytes. / Biochem Biophys Res Comm 1996, 227:168-75. CrossRef
5. Hartley SA, Kozlowski RZ: Electrophysiological consequences of purinergic receptor stimulation in isolated rat pulmonary arterial myocytes. / Circ Res 1997, 80:170-78.
6. Chootip K, Ness KF, Wang Y, Gurney AM, Kennedy C: Regional variation in P2 receptor expression in the rat pulmonary arterial circulation. / Br J Pharmacol 2002, 137:637-46. CrossRef
7. Mc Cormack DG, Barnes PJ, Evans TW: Purinoceptors in the pulmonary circulation of the rat and their role in hypoxic vasoconstriction. / Br J Pharmacol 1989, 98:367-72.
8. Barnes PJ, Liu SF: Regulation of pulmonary vascular tone. / Pharmacol Rev 1995, 47:87-31.
9. Hasséssian H, Burnstock G: Interacting roles of nitric oxide and ATP in the pulmonary circulation of the rat. / Br J Pharmacol 1995, 114:846-50.
10. Rubino A, Burnstock G: Evidence for a P 2 purinoceptor mediator mediation vasoconstriction by UTP, ATP and related nucleotides in the isolated pulmonary vascular bed of the rat. / Br J Pharmacol 1996, 118:1415-420.
11. Liu SF, Mc Cormack DG, Evans TW, Barnes PJ: Characterization and distribution of P 2 -purinoceptor subtypes in rat pulmonary vessels. / J Pharmacol Exp Ther 1989, 251:1204-210.
12. Hartley SA, Kato K, Salter KJ, Kozlowski RZ: Functional evidence for a novel suramin-insensitive pyrimidine receptor in rat small pulmonary arteries. / Circ Res 1998, 83:940-46.
13. Rubino A, Ziabary L, Burnstock G: Regulation of vascular tone by UTP and UDP in isolated rat intrapulmonary arteries. / Eur J Pharmacol 1999, 370:139-43. CrossRef
14. Boarder MR, Webb TE: P2Y receptors: structure and function. In / Handbook of Experimental Pharmacology 151/1; Purinergic and Pyrimidinergic Signalling I: Molecular, Nervous and Urogenitary System Function. Edited by: Abbracchio MP, Williams M. Springer; 2001:65-8.
15. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal M, King BF, Gachet C, Jacobson KA, Weisman GA, Burnstock G: Characterization of the UDP-glucose receptor (re-named here the P2Y 14 receptor) adds diversity to the P2Y receptor family. / Trends Pharmacol Sci 2003, 24:52-5. CrossRef
16. Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden TK: Uridine nucleotide selectivity of three phospholipase C-activating P2 receptors: Identification of a UDP-selective, a UTP-selective, and an ATP- and UTP-specific receptor. / Mol Pharmacol 1996, 50:224-29.
17. Filippov AK, Webb TE, Barnard EA, Brown DA: Dual coupling of heterologously-expressed rat P2Y 6 nucleotide receptors to N-type Ca 2+ and M-type K + currents in rat sympathetic neurones. / Br J Pharmacol 1999, 126:1009-017. CrossRef
18. Robaye B, Boeynaems JM, Communi D: Slow desensitization of the human P2Y 6 receptor. / Eur J Pharmacol 1997, 329:231-36.
19. Bogdanov YD, Wildman SS, Clements MP, King BF, Burnstock G: Molecular cloning and characterisation of rat P2Y 4 nucleotide receptor. / Br J Pharmacol 1988, 124:428-39. CrossRef
20. Suarez-Huerta N, Pouillon V, Boeynaems JM, Robaye B: Molecular cloning and characterization of the mouse P2Y 4 nucleotide receptor. / Eur J Pharmacol 2001, 416:197-02. CrossRef
21. Kennedy C, Leff P: How should P2X-purinoceptors be characterised pharmacologically? / Trends Pharmacol Sci 1995, 16:168-74. CrossRef
22. Lazarowski ER, Boucher RC, Harden TK: Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. / J Biol Chem 2000, 275:31061-1068. CrossRef
23. Lazarowski ER, Boucher RC, Harden TK: Mechanisms of release of nucleotides and integration of their actions as P2X- and P2Y-receptor activating molecules. / Mol Pharmacol 2003, 64:785-95. CrossRef
24. Zimmermann H: Extracellular metabolism of ATP and other nucleotides. / Naunyn-Schmied Arch Pharmacol 2000, 362:299-09. CrossRef
25. Smani T, Iwabuchi S, López-Barneo J, Ure?a J: Differential segmental activation of Ca 2+ -dependent Cl - and K + channels in pulmonary arterial myocytes. / Cell Calcium 2001, 29:369-77. CrossRef
26. Guibert C, Pacaud P, Loirand G: Effect of extracellular ATP on cytosolic Ca 2+ concentration in rat pulmonary artery myocytes. / Am J Physiol 1996, 271:L450-L458.
27. Communi D, Robaye B, Boeynaems JM: Pharmacological characterization of the human P2Y 11 receptor. / Br J Pharmacol 1999, 128:1199-206. CrossRef
28. Gitlin JM, Zanesco A, Stanford SJ, Evans TW, Anning PB, Mitchell JA: The second phase of ATP mediated relaxation is mediated through P2Y 11 receptors. / Br J Pharmacol 2002, 135:210P.
29. Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto SI, Ohishi T, Soga T, Matsushime H, Furuichi K: Molecular cloning of the platelet P2T AC ADP receptor: pharmacological comparison with another ADP receptor, the P2Y 1 receptor. / Mol Pharmacol 2001, 60:432-39.
30. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D: ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. / Arterioscler Thromb Vasc Biol 2005, 24:1-.
31. Kauffenstein G, Hechler B, Cazenave JP, Gachet C: Adenosine triphosphate nucleotides are antagonists at the P2Y 12 receptor. / J Thromb Haem 2004, 2:980-988.
32. Chang K, Hanaoka K, Kumada M, Takuwa Y: Molecular cloning and functional analysis of a novel P2 nucleotide receptor. / J Biol Chem 1995, 270:26152-6158. CrossRef
33. Mellor EA, Maekawa A, Austen KF, Boyce JA: Cysteinyl leukotriene receptor 1 is also a pyrimidergic receptor and is expressed by human mast cells. / Proc Natl Acad Sci USA 2001, 98:7964-969. CrossRef
34. Mellor EA, Austen KF, Boyce JA: Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotrienne receptor antagonists. / J Exp Med 2002, 195:583-92. CrossRef
35. Yoshioka K, Saitoh O, Nakata H: Heteromeric association creates a P2Y-like adenosine receptor. / Proc Natl Acad Sci USA 2001, 98:7617-622. CrossRef
36. Evans RJ, Kennedy C: Characterisation of P2-purinoceptors in the smooth muscle of the rat tail artery: a comparison between contractile and electrophysiological responses. / Br J Pharmacol 1994, 113:853-60.
37. Khakh BS, Michel AD, Humphrey PPA: Inhibition of ectoATPase and Ca-ATPase in rat vas deferens by P 2 -purinoceptor antagonists. / Br J Pharmacol 1995, 115:2P.
38. Chen BC, Lee CM, Lin WW: Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. / Br J Pharmacol 1996, 119:1628-634.
39. Grobben B, Claes P, Roymans D, Esmans EL, Van Onckelen H, Slegers H: Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists. / Br J Pharmacol 2000, 130:139-45. CrossRef - 作者单位：Krongkarn Chootip (1) (2)
Alison M Gurney (1)
Charles Kennedy (1)
1. Department of Physiology and Pharmacology, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, John Arbuthnott Building, 27 Taylor Street, G4 ONR, Glasgow, UK
2. Department of Physiology, Faculty of Medical Science, Naresuan University, 65000, Phitsanulok, Thailand
文摘
Background Uridine 5'-triphosphate (UTP) and uridine 5'-diphosphate (UDP) act via P2Y receptors to evoke contraction of rat pulmonary arteries, whilst adenosine 5'-triphosphate (ATP) acts via P2X and P2Y receptors. Pharmacological characterisation of these receptors in intact arteries is complicated by release and extracellular metabolism of nucleotides, so the aim of this study was to characterise the P2Y receptors under conditions that minimise these problems. Methods The perforated-patch clamp technique was used to record the Ca2+-dependent, Cl- current (ICl,Ca) activated by P2Y receptor agonists in acutely dissociated smooth muscle cells of rat small (SPA) and large (LPA) intrapulmonary arteries, held at -50 mV. Contractions to ATP were measured in isolated muscle rings. Data were compared by Student's t test or one way ANOVA. Results ATP, UTP and UDP (10-4M) evoked oscillating, inward currents (peak = 13-27 pA) in 71-3% of cells. The first current was usually the largest and in the SPA the response to ATP was significantly greater than those to UTP or UDP (P < 0.05). Subsequent currents tended to decrease in amplitude, with a variable time-course, to a level that was significantly smaller for ATP (P < 0.05), UTP (P < 0.001) and UDP (P < 0.05) in the SPA. The frequency of oscillations was similar for each agonist (mean?-1.min-1) and changed little during agonist application. The non-selective P2 receptor antagonist suramin (10-4M) abolished currents evoked by ATP in SPA (n = 4) and LPA (n = 4), but pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) (10-4M), also a non-selective P2 antagonist, had no effect (n = 4, 5 respectively). Currents elicited by UTP (n = 37) or UDP (n = 14) were unaffected by either antagonist. Contractions of SPA evoked by ATP were partially inhibited by PPADS (n = 4) and abolished by suramin (n = 5). Both antagonists abolished the contractions in LPA. Conclusion At least two P2Y subtypes couple to ICl,Ca in smooth muscle cells of rat SPA and LPA, with no apparent regional variation in their distribution. The suramin-sensitive, PPADS-resistant site activated by ATP most resembles the P2Y11 receptor. However, the suramin- and PPADS-insensitive receptor activated by UTP and UDP does not correspond to any of the known P2Y subtypes. These receptors likely play a significant role in nucleotide-induced vasoconstriction.